Oncorus to Present at Chardan 4th Annual Genetic Medicines Conference

Rhea-AI Summary

Oncorus, a clinical stage biopharmaceutical company specializing in viral immunotherapies for cancer treatment, announced that its CEO, Theodore A. Ashburn, will present at the Chardan 4th Annual Genetic Medicines Conference on October 6, 2020, at 4:15 p.m. ET. The company is advancing its lead candidate, ONCR-177, which utilizes a proprietary oncolytic HSV-1 platform designed to target and destroy tumor cells while enhancing the immune response against cancers. For more information, visit www.oncorus.com.

CAMBRIDGE, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical company focused on developing next-generation viral immunotherapies to transform outcomes for cancer patients, today announced that its President and Chief Executive Officer, Theodore (Ted) A. Ashburn, M.D., Ph.D., will present a company overview at the Chardan 4^th Annual Genetic Medicines Conference, to be held virtually on Tuesday, October 6, 2020 at 4:15 p.m. ET.

About Oncorus
Oncorus is a clinical stage biopharmaceutical company focused on developing next-generation viral immunotherapies to transform outcomes for cancer patients. Using its two distinct proprietary platforms, the Company is developing a pipeline of intratumorally and intravenously administered product candidates designed to selectively attack and kill tumor cells and stimulate multiple arms of the immune system against tumors. Oncorus’ lead product candidate, ONCR-177, is an intratumorally administered viral immunotherapy based on its oncolytic HSV-1 platform, referred to as the oHSV Platform, which leverages the Herpes Simplex Virus type 1, or HSV-1, a virus which has been clinically proven to effectively treat certain cancers. For more information, please visit www.oncorus.com.

Investors:
John McCabe
ir@oncorus.com

Media:
Liz Melone
media@oncorus.com

FAQ

What is the date and time of Oncorus' presentation at the Chardan 4th Annual Genetic Medicines Conference?

Oncorus will present on October 6, 2020, at 4:15 p.m. ET.

Who is presenting Oncorus' company overview at the conference?

The presentation will be delivered by Theodore A. Ashburn, President and CEO of Oncorus.

What is the focus of Oncorus' research and development?

Oncorus focuses on developing next-generation viral immunotherapies aimed at transforming cancer treatment outcomes.

What is ONCR-177 and how does it work?

ONCR-177 is Oncorus' lead product candidate, utilizing an oncolytic HSV-1 platform to selectively kill tumor cells and stimulate immune responses.

Where can I find more information about Oncorus?

More information is available on Oncorus' official website at www.oncorus.com.